NCT00002350View on ClinicalTrials.gov

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
BIOLOGICAL

APL 400-003

Trial Locations (1)

19104

Univ of Pennsylvania Med Ctr, Philadelphia

Sponsors

Lead Sponsor

Apollon
All Listed Sponsors
lead

Apollon

INDUSTRY

NCT00002350 - A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients | Biotech Hunter | Biotech Hunter